Read More Pharma Industry News ZYN002 misses pivotal Fragile X trial — What does the setback mean for Harmony’s pipeline and stock outlook? Harmony’s ZYN002 fails key Fragile X trial, sending HRMY stock lower. Find out why placebo effects mattered and what’s next for its pipeline. byPallavi MadhirajuSeptember 27, 2025